PPM-18

Synonyms: NSC 73233
PPM-18 (NSC 73233) 是一种 Vitamin K (MS-T77222) 类似物,可阻止 LPS 诱导的 IκBα 降解,从而抑制 NF-κB 激活及其核转位,并抑制 LPS 诱导的亚硝酸盐生成和 iNOS 表达;它还可抑制 HDAC6,诱导 ROS 积累,激活 AMPK,抑制 mTORC1 和 PI3K/AKT 通路,启动自噬 (Autophagy) 并诱导凋亡 (Apoptosis),在斑马鱼和小鼠癫痫模型中抑制癫痫发作,预防 LPS 诱导的致死毒性和延迟性低血压,对白血病和膀胱癌具有抗癌活性,可用于感染性休克、膀胱癌和动脉粥样硬化的相关研究。
产品编号: MS-J44110 纯度: 99.17% CAS No.: 65240-86-0 分子式: C17H11NO3 分子量: 277.27
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

PPM-18 (NSC 73233) 是一种 Vitamin K (MS-T77222) 类似物,可阻止 LPS 诱导的 IκBα 降解,从而抑制 NF-κB 激活及其核转位,并抑制 LPS 诱导的亚硝酸盐生成和 iNOS 表达;它还可抑制 HDAC6,诱导 ROS 积累,激活 AMPK,抑制 mTORC1 和 PI3K/AKT 通路,启动自噬 (Autophagy) 并诱导凋亡 (Apoptosis),在斑马鱼和小鼠癫痫模型中抑制癫痫发作,预防 LPS 诱导的致死毒性和延迟性低血压,对白血病和膀胱癌具有抗癌活性,可用于感染性休克、膀胱癌和动脉粥样硬化的相关研究。

生物实验数据

生物活性 PPM-18 (NSC 73233) is a Vitamin K (MS-T77222) analog that prevents LPS-induced IκBα degradation, thereby inhibiting NF-κB activation and its nuclear translocation, and suppresses LPS-induced nitrite production and iNOS expression; it also inhibits HDAC6, induces ROS accumulation, activates AMPK, inhibits the mTORC1 and PI3K/AKT pathways, initiates autophagy (Autophagy), and induces apoptosis (Apoptosis), suppresses seizures in zebrafish and mouse epilepsy models, prevents LPS-induced lethal toxicity and delayed hypotension, exhibits anticancer activity against leukemia and bladder cancer, and can be used for research related to septic shock, bladder cancer, and atherosclerosis.
IC50 & Target

iNOS

 

HDAC6

 

mTORC1

 

体外研究
(In Vitro)

PPM-18 (0.1-10 µM; 24 h) 可剂量依赖性地抑制脂多糖 (LPS) 诱导的大鼠肺泡巨噬细胞中一氧化氮的生成 (以亚硝酸盐含量衡量),在 10 µM 时抑制作用达到峰值。
PPM-18 (3-10 µM; 24 h) 可抑制脂多糖 (LPS) 诱导的大鼠肺泡巨噬细胞中 iNOS 蛋白表达。
PPM-18 (3-10 µM; preincubated prior to 6 h LPS stimulation) 可抑制脂多糖 (LPS) 诱导的大鼠肺泡巨噬细胞中 iNOS mRNA 累积。
PPM-18 (10 µM; 60 min preincubation prior to 30 min LPS stimulation) 可抑制脂多糖 (LPS) 诱导的大鼠肺泡巨噬细胞中 NF-κB p65 的核内聚集。
PPM-18 (10-30 µM; 60 min preincubation prior to 30 min LPS stimulation for whole-cell assays) 可抑制脂多糖 (LPS) 诱导的完整大鼠肺泡巨噬细胞中 NF-κB-DNA 结合活性,但不会直接干扰分离核提取物中的 NF-κB-DNA 结合。
PPM-18 (10 µM; 24 h) 可抑制 LPS 诱导大鼠肺泡巨噬细胞释放 TNF-α。
PPM-18 (5-20 μM; 6-24 h) 呈剂量和时间依赖性降低膀胱癌 T24 和 EJ 细胞的存活率。
PPM-18 (5-15 μM; 24 h) 可呈剂量依赖性诱导膀胱癌 T24 和 EJ 细胞发生自噬,该效应可通过 p62 表达降低及 LC3B II 表达升高来检测。
PPM-18 (10 μM; 1 h) 可完全抑制剪切诱导的 NFκB 亚基 p50 和 p65 的核转位。

Western Blot Analysis

Cell Line: rat alveolar macrophages
Concentration: 3-10 µM
Incubation Time: 24 h
Result: Inhibited LPS-induced iNOS protein expression, with 10 µM showing a greater inhibitory effect than 3 µM.

RT-PCR

Cell Line: rat alveolar macrophages
Concentration: 3-10 µM
Incubation Time: preincubated prior to 6 h LPS stimulation
Result: Inhibited LPS-induced accumulation of iNOS mRNA, with 10 µM showing near-complete inhibition and 3 µM showing partial inhibition.

Western Blot Analysis

Cell Line: rat alveolar macrophages
Concentration: 10 µM
Incubation Time: 60 min preincubation prior to 30 min LPS stimulation
Result: Significantly inhibited LPS-induced nuclear accumulation of NF-κB p65.

ELISA Assay

Cell Line: rat alveolar macrophages
Concentration: 10 µM
Incubation Time: 24 h
Result: Inhibited LPS-induced TNF-α increase, reducing TNF-α levels from 2711 pg/mL (LPS alone) to 260 pg/mL (P < 0.001).

Cell Viability Assay

Cell Line: human bladder cancer T24 and EJ cells
Concentration: 5-20 μM (dose-response); 15 μM (time-response)
Incubation Time: 24 h (dose-response); 6-24 h (time-response)
Result: Reduced T24 and EJ cell viability in a dose- and time-dependent manner.
Significantly decreased viability at 10, 15, 20 μM (***p < 0.001 vs. control) for both cell lines at 24 h.
Reduced viability significantly at 18 and 24 h (***p < 0.001 vs. control) for both lines with 15 μM treatment.
体内研究
(In Vivo)

PPM-18 (5-15 mg/kg;腹腔注射;单次;LPS 处理前 2 小时) 对 Balb/c 小鼠中 LPS 诱导的致死性脓毒症具有剂量依赖性保护作用,在 15 mg/kg 剂量下的保护率为 70%。
PPM-18 (15 mg/kg;静脉注射;单次;LPS 处理前 20 分钟) 可在大鼠内毒素休克模型中预防延迟性低血压,并抑制 LPS 诱导的血浆总亚硝酸盐水平升高。
PPM-18 (10 mg/kg;瘤内注射;每日;持续 30 天) 可抑制膀胱癌异种移植物的生长,通过 ROS 和 AMPK 通路促进肿瘤细胞自噬与凋亡,将小鼠存活率提升至 85.7%,且表现出较低的体内毒性。

Animal Model: Balb/c (20-25 g)
Dosage: 5 mg/kg; 15 mg/kg
Administration: i.p.; single dose; 2 hours prior to LPS
Result: Reduced LPS-induced mortality to 55% at 5 mg/kg.
Reduced LPS-induced mortality to 30% at 15 mg/kg.
Conferred 70% protection at 15 mg/kg.
Animal Model: Wistar (male, 300-350 g)
Dosage: 15 mg/kg
Administration: i.v.; single dose; 20 minutes prior to LPS
Result: Maintained mean arterial pressure at 100 mmHg at 3 hours post-LPS, a significant difference compared to LPS-only controls (P < 0.001).
Reduced total plasma nitrite levels to 10.5 μM at 360 minutes post-LPS, similar to sham-operated rats.
Animal Model: BALB/c nude (female, 4-5 weeks old, subcutaneous xenograft of human EJ bladder cancer cells)
Dosage: 10 mg/kg
Administration: intratumoral injection; daily; 30 days
Result: Significantly reduced tumor volume compared to controls.
Increased mouse survival rate to 85.7% vs. 14.3% in controls.
Increased tumor tissue expression of cleaved caspase-3, LC3B, and phospho-AMPK.
Reduced tumor tissue Ki67 expression.
Increased tumor cell apoptosis measured by TUNEL staining.
Increased tumor ROS production measured by DHE staining.
Caused no significant change in mouse body weight.
Showed no major organ toxicity observed via H&E staining of heart, liver, spleen, lung, and kidney.
性状 固体
颜色 Orange to red

化学信息

分子量 277.27
分子式 C17H11NO3
CAS No. 65240-86-0
别名 NSC 73233

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

PPM-18 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础